Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-04-22-Speech-2-194"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20080422.46.2-194"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Therapeutic use of human organs involving the substitution of a non-functional organ for another one coming from a donor can, if successful, restore a full and healthy life for many years to people who would otherwise often require intensive care.
Although the use of human organs for transplantation has steadily increased in EU countries in recent decades, the number of people requiring a transplant is greater than the number of organs available for transplant. Official studies state that nearly 40 000 people are currently on waiting lists in Western Europe. Mortality rate while waiting for a heart, liver or lung transplant usually ranges from 15 to 30%.
Donor testing is important in minimising the risks to the recipient. As mentioned in the report, it is essential to screen donors and establish the presence or absence of risk of disease transmission, which involves a set of examinations. However, there is currently no consensus between Member States on these tests. Hence the importance of this report to encourage greater cooperation."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples